CMXC — Cell MedX Income Statement
0.000.00%
Last trade - 00:00- $8.92m
- $9.97m
- $0.00m
Annual income statement for Cell MedX, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.096 | 0.007 | 0.006 | 0.003 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.086 | 0.004 | 0.004 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.67 | 1.13 | 0.732 | 0.678 | 0.45 |
| Operating Profit | -0.67 | -1.04 | -0.725 | -0.672 | -0.448 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -0.906 | -1.09 | -0.911 | -0.697 | -0.495 |
| Net Income After Taxes | -0.906 | -1.09 | -0.911 | -0.697 | -0.495 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.906 | -1.09 | -0.911 | -0.697 | -0.495 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.906 | -1.09 | -0.911 | -0.697 | -0.495 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.02 | -0.022 | -0.012 | -0.011 | -0.008 |